巴西多发性硬化症患者使用醋酸格拉替雷治疗的依从性经验
Adherence to glatiramer acetate treatment for multiple sclerosis: the Brazilian experience.
作者信息
de Oliveira Tatiana de Melo Gomes, Fiore Ana Patricia Peres, Fragoso Yára Dadalti
机构信息
TEVA Pharmaceutical, Brazil;
出版信息
Patient Prefer Adherence. 2008 Feb 2;2:41-6. doi: 10.2147/ppa.s2255.
Multiple sclerosis is a chronic disease characterized by demyelination and neurodegeneration of the central nervous system. Immunomodulatory treatment is possible at an early stage of the disease, and consists of injections of either beta-interferon or glatiramer acetate. The drugs are not curative, and the need for frequent injections may give rise to a serious problem regarding adherence to treatment. The present study analyzed the database of all Brazilian patients using glatiramer acetate between June 2003 and December 2006 who had enrolled in the patient program run by the pharmaceutical company commercializing the drug. The rate of treatment discontinuation was 10% over this period, and the main reason for suspending the drug was medical decisions (47% of all discontinuations), rather than side effects or the patient's choice. The present work did not take into consideration the regularity of injections and the main objective was to assess discontinuation. It was concluded that adequate healthcare, education, and a specific program for patients were the factors responsible for this 90% adherence to glatiramer acetate treatment in Brazil.
多发性硬化症是一种以中枢神经系统脱髓鞘和神经退行性变为特征的慢性疾病。在疾病早期可进行免疫调节治疗，治疗方法包括注射β-干扰素或醋酸格拉替雷。这些药物无法治愈疾病，且频繁注射的需求可能引发治疗依从性方面的严重问题。本研究分析了2003年6月至2006年12月期间所有使用醋酸格拉替雷的巴西患者的数据库，这些患者参加了销售该药物的制药公司开展的患者项目。在此期间治疗中断率为10%，停药的主要原因是医疗决定（占所有停药情况的47%），而非副作用或患者的选择。本研究未考虑注射的规律性，主要目的是评估停药情况。研究得出结论，充足的医疗保健、教育以及针对患者的特定项目是巴西90%的患者坚持醋酸格拉替雷治疗的原因。
Zotero 插件